Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humira Managed Care Coverage At 95%; Abbott Raises Sales Forecast

Executive Summary

Abbott's Humira is being reimbursed by 95% of managed care organizations three months after the launch of the tumor necrosis factor inhibitor for rheumatoid arthritis

You may also be interested in...



Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next

Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29

Humira Takes Nearly 20% Of Enbrel Share; Abbott Eyes Psoriasis Market Next

Abbott sees psoriasis as the next large market opportunity for Humira after rheumatoid arthritis, Immunology General Manager Tim Walbert said during Abbott's R&D Day in New York May 29

Tidbits From The SG Cowen Health Care Conference

King/Elan deal in jeopardy?: King is "evaluating the effect" that FTC's investigation into Elan's Skelaxin will have on its proposed acquisition of Elan's primary care business. King is "evaluating what our rights are under our contract," company says at SG Cowen March 19. FTC opened an investigation into Elan's "Orange Book" patent listings for the muscle relaxant (1"The Pink Sheet" March 17, In Brief). King reiterated that it will not purchase the sleep agent Sonata as a stand-alone product. "The transaction is not structured that way." The $850 mil. deal, which has a deadline of July 31, would add 400 sales reps to King's 800-person force ("The Pink Sheet" Feb. 3, p. 29)...

Related Content

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel